ena-STUDY-NETHERLANDS CANCER INSTITUTE-30-03-2018-09:32:14:483-3015
Genomic landscape of BRCA1-deficient tumors upon PARPi treatment
Selective elimination of BRCA1-deficient cells by inhibitors of poly(ADP-ribose) polymerase (PARP) is a prime example of the concept of synthetic lethality in cancer therapy. This interaction is counteracted by the restoration of BRCA1-independent homologous recombination through loss of factors such as 53BP1 and RIF1, which inhibit end resection of DNA double strand breaks. To identify additional factors involved in this process, we performed RNA-seq and CNV-seq analysis for KB1P and KBP1M mice upon PARPi treatment
Selective elimination of BRCA1-deficient cells by inhibitors of poly(ADP-ribose) polymerase (PARP) is a prime example of the concept of synthetic lethality in cancer therapy. This interaction is counteracted by the restoration of BRCA1-independent homologous recombination through loss of factors such as 53BP1 and RIF1, which inhibit end resection of DNA double strand breaks. To identify additional factors involved in this process, we performed RNA-seq and CNV-seq analysis for KB1P and KBP1M mice upon PARPi treatment